Aims: Metastatic brain tumors are the most commonly seen intracranial lesion in adults and an important cause of morbidity and mortality in patients with cancer. This study aimed to evaluate the postoperative mortality, morbidity, and survival rates of patients who underwent surgery in our clinic for metastatic brain tumorsMethod: Clinical data of 131 patients, including age, sex, symptoms, localization, primer site, surgical methods, resection, complications and recurrence were collected.Results: Fifty patients (38.1%) were female, and 81 (61.8%) patients were male. The average age of the patients was 54,9. The most common reason for hospital admission was headache (68.7%). Lesions were detected in the cerebral hemisphere in 108 (82.4%) patients and the posterior fossa in 23 (17.5%) patients, and 16 (12.2%) patients had multiple lesions. All patients (n=131) underwent surgery with neuronavigation. Total resection was performed in 25 (19%) patients, gross total resection in 83 (63.3%), subtotal resection in 18 (13.7%), and biopsy in 5 (3.8%). The most commonly seen tumor originated from the lungs (n=63, 48%), according to the histopathological examination. The mean overall survival was 5.3 (range, 1–36) months during the follow-up period. Twelve (9.1%) patients had recurrence and underwent surgery again.Conclusion: Multidisciplinary treatment methods are used in the treatment of metastatic brain tumors. Effective surgical intervention to eliminate peritumoral edema and increased intracranial pressure improves postoperative survival rates. In addition, post-surgical whole-brain radiotherapy reduces recurrence and improves survival.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.